A

AbbVie

Global biopharmaceutical company developing medicines

Director – Computational Hitgen / Leadgen Team Lead

Full-Time
$160.5k - $305k/yr+ Long-term incentive program
Expert
Bachelor's, Master's, PhD
North Chicago, IL, USA
In Person
Biology & BiotechQuantitative Biology & Biostatistics

About the job

Requirements
  • A Bachelor's degree or equivalent education in a science-related field with typically more than 18 years of related work experience, a Master's degree or equivalent education with typically more than 16 years of related work experience, or a PhD in Science or a related field with typically 10 or more years of related work experience.
  • Demonstrated success in coaching, mentoring, and people management.
  • Experience setting and driving strategy while leading a global team.
  • Experience leading multiple complex simultaneous research programs or initiatives.
  • Knowledge and experience in modern computational approaches for drug discovery.
  • Excellent written and verbal communication and critical evaluation and data-driven decision-making skills.
  • Strong analytical and problem-solving skills, with the ability to think critically and creatively and provide solutions individually and collaboratively with internal experts.
  • Proven team leadership and management abilities, including mentoring, guiding, supervising, and developing scientific personnel with various backgrounds and training levels.
  • Strong interpersonal skills and the ability to collaborate with diverse internal groups and external partners.
  • Ability to create an inclusive environment where diverse ideas, viewpoints, and backgrounds are valued, and willingness and ability to lead inclusively and consider all points of view.
Responsibilities
  • Lead development of a cohesive collection of cutting-edge methods and workflows to address small-molecule portfolio needs, including predicting binding affinities, predicting pharmacological properties such as pharmacokinetic parameters, and rapidly sampling enumerated and artificial-intelligence-generated chemical spaces.
  • Work closely with small-molecule leadership teams to identify and address gaps where computational predictions are needed.
  • Advance drug discovery expertise across Computational Drug Discovery and collaborate with cross-disciplinary Research and Development and Information Research teams to advance programs and implement computational capabilities across programs.
  • Provide leadership and guidance across the early-stage small-molecule portfolio to deliver computational tools and workflows that achieve desirable hit and lead criteria and align functions with longer-term organizational and artificial-intelligence-native drug discovery strategies.
  • Guide HitGen/LeadGen team members in benchmarking experiments to evaluate model performance and domain of applicability for the small-molecule portfolio.
  • Establish processes for selecting approaches that best suit project needs.
  • Provide expert advice and shared knowledge to direct reports, peers, and senior management.
  • Present program updates and research strategies to functional and non-functional leaders and potential and existing partners.
  • Maintain awareness of emerging literature and science in the field and author scientific disclosures and publications.
  • Maintain a scientific presence outside the company through appropriate publication and conference abstract submissions highlighting innovative learnings in artificial-intelligence-native drug discovery.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 13th, 2026
AbbVie vs Novo Nordisk: AbbVie's $61.2B revenue growth makes it the better 2026 buy

A Motley Fool comparison of AbbVie and Novo Nordisk concludes AbbVie is the better long-term buy in 2026, even though Novo looks cheaper. AbbVie's 2025 revenue rose about 8.6% to $61.2 billion, but net income was $4.2 billion. Novo Nordisk's revenue grew 6.4% to $46.3 billion, with net income of $15.3 billion. Novo trades at 11.7 times forward earnings against AbbVie's 20.2. Analysts expect Novo's 2026 sales to fall about 3% on pricing pressure and rivalry from Eli Lilly. AbbVie is forecast to grow net income to $14.6 billion on $67.2 billion in sales, helped by its $10.9 billion Apogee Therapeutics deal and its Skyrizi and Rinvoq drugs.

Yahoo Finance
Oct 13th, 2026
AbbVie shares at $281.12 trade 43.5% below DCF fair value of $497.77 after pipeline wins

AbbVie shares have climbed to $281.12, up 9.33% in a month and 22.59% so far this year, after a run of clinical and regulatory news. Total shareholder return is 25.85% over one year. The news includes Phase 3 Crohn's disease results for SKYRIZI and RINVOQ, and FDA Breakthrough Therapy Designations for Temab-A in colorectal and lung cancer. AbbVie also released early obesity data for ABBV-295 and Phase 2 atopic dermatitis results for zumilokibart. Simply Wall St's most followed narrative puts fair value at $278.61, leaving the stock 1% overvalued. Its discounted cash flow model estimates $497.77, which would put the shares about 43.5% below fair value. Risks include tighter drug price pressure and faster than expected competition for Skyrizi and Rinvoq.

Yahoo Finance
Oct 13th, 2026
AbbVie vs Eli Lilly: Lilly's 44.7% revenue surge to $65.2B makes it the 2026 pick

A comparison of AbbVie and Eli Lilly favours Eli Lilly for long-term investors, driven by its strong weight-loss and diabetes drug franchise. Lilly's 2025 revenue rose 44.7% to $65.2 billion, with net income of $20.6 billion. AbbVie's revenue grew 8.6% to $61.2 billion, with net income of $4.2 billion, as Skyrizi and Rinvoq replace ageing Humira sales. Lilly trades at a forward price-to-earnings ratio of 33.1x, against 19.8x for AbbVie. Lilly expects 2026 revenue of up to $85.2 billion, helped by Zepbound, Mounjaro and a new pill, Foundayo. AbbVie forecasts 2026 sales of $67.2 billion and net income of $14.6 billion. It is also acquiring Apogee Therapeutics.

Finanzen.net
Oct 12th, 2026
S&P 500 stock AbbVie share: This is how much profit an investment in AbbVie 10 years ago would have generated.

S&P 500 stock AbbVie share: This is how much profit an investment in AbbVie 10 years ago would have generated. October 12, 2026, 4:00 p.m. Invested in AbbVie years ago: This is how much investors would have earned. Exactly 10 years ago today, trading in the AbbVie share took place on the NYSE. The stock ended the day at USD 61.21. With a USD 100 investment 10 years ago, investors would now have 1.634 AbbVie shares in their portfolio. Calculated using the most recent closing price from October 9, 2026 (USD 276.47), the investment would now be worth USD 451.67. That means the value of the original investment would have increased by 351.67 percent. The market value of AbbVie recently amounted to USD 487.20 billion. Please note that stock splits and dividend payments are not taken into account in the above calculation. finanzen.net editorial team Selected leveraged products on AbbVie. With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired leverage and we will show you suitable open-end products on AbbVie. | Name | Leverage | KO | Issuer | | Mini Future Long on AbbVie | 4.72 | 239.26 | Morgan Stanley | | Turbo Long on AbbVie | 4.60 | 219.21 | Morgan Stanley | | Mini Future Long on AbbVie | 4.51 | 234.17 | Morgan Stanley | | Turbo Long on AbbVie | 4.31 | 215.06 | Morgan Stanley | | Turbo Long on AbbVie | 4.05 | 210.62 | Morgan Stanley | You can obtain the base prospectus as well as the final terms and the key information documents here: MR42P0, MR2ECS, MR42NZ, MR14JZ, MN9YRD. Please also note the further information** on this advertisement. Risk notice: On average, 7 out of 10 retail investors suffer losses when trading turbo certificates. Turbo certificates are highly risky products and are not suitable for long-term investment strategies.

Yahoo Finance
Oct 11th, 2026
AbbVie's yield hits 2.6%, its lowest since 2018, but dividend growth keeps it an income pick

AbbVie's dividend yield has fallen to about 2.6%, its lowest since early 2018. The drop comes from a share price that has risen faster than the dividend, not from any cut. The drugmaker has raised its dividend for 54 consecutive years, including its time as part of Abbott Labs. The payout is up almost 333% since 2013, while the stock has gained roughly 676%. Growth looks set to continue. Humira's successors, Skyrizi and Rinvoq, are on track for combined 2026 sales of over $29 billion, against Humira's peak of about $22 billion in 2021. If dividend growth matches the past five years' pace, yield on cost could top 4.6% within 10 years. Consensus analyst targets imply only about 5% upside over 12 months.